In the last decades, CNPY2 was found to regulate the progression of human diseases mainly though modifying various downstream signaling pathways including p53 in colorectal cancer [25], NF-κB pathway in non-small cell lung cancer [28], as well as the PERK signaling pathway in myocardial ischemia reperfusion injury [29]. This evidence concerns the gene NFKB1 and non-small cell lung carcinoma.